Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis

Pacing Clin Electrophysiol. 2018 Jul;41(7):878. doi: 10.1111/pace.13390. Epub 2018 Jun 8.

Authors

Ronpichai Chokesuwattanaskul¹, Charat Thongprayoon², Tanyanan Tanawuttiwat³, Wisit Kaewput⁴, Pavida Pachariyanon⁵, Wisit Cheungpasitporn⁶

Affiliations

¹ Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
² Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA.
³ Division of Cardiology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
⁴ Department of Military and Community Medicine, Phramongkutklao College of Medicine Bangkok, Thailand.
⁵ Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
⁶ Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

PMID: 29791015
DOI: 10.1111/pace.13390

No abstract available

Keywords: apixaban; atrial fibrillation; bleeding complication; meta-analysis; thromboembolic events; vitamin K antagonist; warfarin.

Publication types

Letter
Comment

MeSH terms

Humans
Kidney Failure, Chronic*
Pyrazoles
Pyridones
Warfarin*

Substances

Pyrazoles
Pyridones
apixaban
Warfarin